Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of ≥ 1% by the U.S. Food and Drug Administration.

Mountzios G, Remon J, Novello S, Blais N, Califano R, Cufer T, Dingemans AM, Liu SV, Peled N, Pennell NA, Reck M, Rolfo C, Tan D, Vansteenkiste J, West H, Besse B.

Ann Oncol. 2019 Sep 3. pii: mdz295. doi: 10.1093/annonc/mdz295. [Epub ahead of print] No abstract available.

PMID:
31504132
2.

Management of urachal cancer: A review by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada.

Hamilou Z, North S, Canil C, Wood L, Hotte S, Sridhar S, Soulières D, Latour M, Taussky D, Kassouf W, Blais N.

Can Urol Assoc J. 2019 Jul 23. doi: 10.5489/cuaj.5946. [Epub ahead of print] Review. No abstract available.

PMID:
31348743
3.

Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes.

Couëtoux du Tertre M, Marques M, Tremblay L, Bouchard N, Diaconescu R, Blais N, Couture C, Pelsser V, Wang H, Higenell V, Izzi L, Gambaro K, Hoffert C, Srivastava A, Spatz A, Rousseau C, McNamara S, Cohen V, Batist G, Agulnik J.

Mol Cancer Ther. 2019 Sep;18(9):1628-1636. doi: 10.1158/1535-7163.MCT-19-0105. Epub 2019 Jun 26.

PMID:
31243098
4.

Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.

Melosky B, Bradbury P, Tu D, Florescu M, Reiman A, Nicholas G, Basappa N, Rothenstein J, Goffin JR, Laurie SA, Wheatley-Price P, Leighl N, Goss G, Reaume MN, Butts C, Murray N, Card C, Ko J, Blais N, Gray S, Lui H, Brown-Walker P, Kaurah P, Prentice LM, Seymour L.

Lung Cancer. 2019 Jul;133:48-55. doi: 10.1016/j.lungcan.2019.04.027. Epub 2019 May 1.

PMID:
31200828
5.

Design and Characterization of Protein E-PilA, a Candidate Fusion Antigen for Nontypeable Haemophilus influenzae Vaccine.

Blais N, Somers D, Faubert D, Labbé S, Castado C, Ysebaert C, Gagnon LP, Champagne J, Gagné M, Martin D.

Infect Immun. 2019 Jul 23;87(8). pii: e00022-19. doi: 10.1128/IAI.00022-19. Print 2019 Aug.

6.

Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma.

Warren M, Kolinsky M, Canil CM, Czaykowski P, Sridhar SS, Black PC, Booth CM, Kassouf W, Eapen L, Mukherjee SD, Blais N, Eigl BJ, Winquist E, Basappa NS, North SA; GUMOC.

Can Urol Assoc J. 2019 Apr 26:318-327. doi: 10.5489/cuaj.6015. [Epub ahead of print] No abstract available.

7.

Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.

Laurie SA, Banerji S, Blais N, Brule S, Cheema PK, Cheung P, Daaboul N, Hao D, Hirsh V, Juergens R, Laskin J, Leighl N, MacRae R, Nicholas G, Roberge D, Rothenstein J, Stewart DJ, Tsao MS.

Curr Oncol. 2019 Feb;26(1):e81-e93. doi: 10.3747/co.26.4116. Epub 2019 Feb 1.

8.

"I Am Because We Are": Awakening Revolutionary Patient-Centered Care.

Blais NC.

J Emerg Nurs. 2019 Mar;45(2):211-213. doi: 10.1016/j.jen.2018.12.018. No abstract available.

PMID:
30846142
9.

Extended thromboprophylaxis with low-molecular weight heparin (LMWH) following abdominopelvic cancer surgery.

Carrier M, Altman AD, Blais N, Diamantouros A, McLeod D, Moodley U, Nguyen C, Young S, Schwenter F.

Am J Surg. 2019 Sep;218(3):537-550. doi: 10.1016/j.amjsurg.2018.11.046. Epub 2018 Dec 16.

PMID:
30595331
10.

Shifting the Paradigm from Child Neglect to Meeting the Needs of Children: A Qualitative Exploration of Parents' Perspectives.

Elias TI, Blais N, Williams K, Burke JG.

Soc Work Public Health. 2018;33(7-8):407-418. doi: 10.1080/19371918.2018.1543625. Epub 2018 Nov 30.

PMID:
30497349
11.

Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges.

Nixon NA, Blais N, Ernst S, Kollmannsberger C, Bebb G, Butler M, Smylie M, Verma S.

Curr Oncol. 2018 Oct;25(5):e373-e384. doi: 10.3747/co.25.3840. Epub 2018 Oct 31. Review.

12.

Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus.

Carrier M, Blais N, Crowther M, Kavan P, Le Gal G, Moodley O, Shivakumar S, Tagalakis V, Wu C, Lee AYY.

Curr Oncol. 2018 Oct;25(5):329-337. doi: 10.3747/co.25.4266. Epub 2018 Oct 31.

13.

Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

Melosky B, Cheema P, Agulnik J, Albadine R, Bebb DG, Blais N, Burkes R, Butts C, Card PB, Chan AMY, Hirsh V, Ionescu DN, Juergens R, Morzycki W, Poonja Z, Sangha R, Tehfe M, Tsao MS, Vincent M, Xu Z, Liu G.

Curr Oncol. 2018 Oct;25(5):317-328. doi: 10.3747/co.25.4379. Epub 2018 Oct 31. Review.

14.

Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time.

Dubé C, Douketis JD, Moffat KA, Schulman S, Blais N.

Thromb Res. 2018 Nov;171:62-67. doi: 10.1016/j.thromres.2018.09.051. Epub 2018 Sep 19.

PMID:
30261356
15.

Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials.

Karakiewicz PI, Zaffuto E, Kapoor A, Basappa NS, Bjarnason GA, Blais N, Breau RH, Canil C, Drachenberg D, Hotte SJ, Jeldres C, Jewett MAS, Kassouf W, Kollmannsberger C, Lavallée LT, Maloni R, Patenaude F, Pouliot F, Reaume MN, Sabbagh R, Shayegan B, So A, Soulières D, Tanguay S, Wood L, Bandini M.

Can Urol Assoc J. 2018 Jun;12(6):173-180. doi: 10.5489/cuaj.5187.

16.

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.

Bradbury PA, Morris DG, Nicholas G, Tu D, Tehfe M, Goffin JR, Shepherd FA, Gregg RW, Rothenstein J, Lee C, Kuruvilla S, Keith BD, Torri V, Blais N, Hao D, Korpanty GJ, Goss G, Melosky BL, Mates M, Leighl N, Ayoub JP, Sederias J, Feilotter H, Seymour L, Laurie SA.

Lung Cancer. 2018 Jun;120:142-148. doi: 10.1016/j.lungcan.2018.03.005. Epub 2018 Mar 9.

PMID:
29748010
17.

Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab.

Acero Brand FZ, Suter N, Adam JP, Faulques B, Maietta A, Soulières D, Blais N.

J Immunother Cancer. 2018 Mar 16;6(1):22. doi: 10.1186/s40425-018-0332-z.

18.

Standardizing biomarker testing for Canadian patients with advanced lung cancer.

Melosky B, Blais N, Cheema P, Couture C, Juergens R, Kamel-Reid S, Tsao MS, Wheatley-Price P, Xu Z, Ionescu DN.

Curr Oncol. 2018 Feb;25(1):73-82. doi: 10.3747/co.25.3867. Epub 2018 Feb 28.

19.

Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.

Reaume MN, Basappa NS, Wood L, Kapoor A, Bjarnason GA, Blais N, Breau RH, Canil C, Cheung P, Conter HJ, Hotte SJ, Jeldres C, Jewett MAS, Karakiewicz PI, Kollmannsberger C, Patenaude F, So A, Soulières D, Venner P, Violette P, Zalewski P, Chappell H, North SA; Kidney Cancer Research Network of Canada.

Can Urol Assoc J. 2017 Oct;11(10):310-320. doi: 10.5489/cuaj.4769. No abstract available.

20.

Position of the French Working Group on Perioperative Haemostasis (GIHP) on viscoelastic tests: What role for which indication in bleeding situations?

Roullet S, de Maistre E, Ickx B, Blais N, Susen S, Faraoni D, Garrigue D, Bonhomme F, Godier A, Lasne D; GIHP.

Anaesth Crit Care Pain Med. 2019 Oct;38(5):539-548. doi: 10.1016/j.accpm.2017.12.014. Epub 2018 Feb 3.

21.

Management of stage III non-small cell lung cancer.

Tabchi S, Kassouf E, Rassy EE, Kourie HR, Martin J, Campeau MP, Tehfe M, Blais N.

Semin Oncol. 2017 Jun;44(3):163-177. doi: 10.1053/j.seminoncol.2017.10.009. Epub 2017 Oct 18. Review.

PMID:
29248128
22.

An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP).

Corrales-Rodríguez L, Arrieta O, Mas L, Báez-Saldaña R, Castillo-Fernández O, Blais N, Martín C, Juárez M, Khanna P, Ramos-Esquivel A, Bacon L, Rojas L, Wills B, Oblitas G, Pérez MA, Cuello M, Cardona AF; CLICaP.

Lung Cancer. 2017 Nov;113:30-36. doi: 10.1016/j.lungcan.2017.08.022. Epub 2017 Sep 11.

PMID:
29110845
23.

Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer.

Bellmunt J, Eigl BJ, Senkus E, Loriot Y, Twardowski P, Castellano D, Blais N, Sridhar SS, Sternberg CN, Retz M, Pal S, Blumenstein B, Jacobs C, Stewart PS, Petrylak DP.

Ann Oncol. 2017 Oct 1;28(10):2481-2488. doi: 10.1093/annonc/mdx400.

PMID:
28961845
24.

Factors influencing treatment selection and survival in advanced lung cancer.

Tabchi S, Kassouf E, Florescu M, Tehfe M, Blais N.

Curr Oncol. 2017 Apr;24(2):e115-e122. doi: 10.3747/co.24.3355. Epub 2017 Apr 27.

25.

Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer.

Reck M, Blais N, Juhasz E, Gorbunova V, Jones CM, Urban L, Orlov S, Barlesi F, Kio E, Keilholz U, Qin Q, Qian J, Nickner C, Dziubinski J, Xiong H, Mittapalli RK, Dunbar M, Ansell P, He L, McKee M, Giranda V, Ramalingam SS.

J Thorac Oncol. 2017 Jul;12(7):1098-1108. doi: 10.1016/j.jtho.2017.04.010. Epub 2017 Apr 29.

26.

Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine.

Tabchi S, Blais N.

Front Oncol. 2017 Mar 29;7:52. doi: 10.3389/fonc.2017.00052. eCollection 2017. Review.

27.

Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation.

Blais N, Gagné M, Hamuro Y, Rheault P, Boyer M, Steff AM, Baudoux G, Dewar V, Demers J, Ruelle JL, Martin D.

J Virol. 2017 Jun 9;91(13). pii: e02437-16. doi: 10.1128/JVI.02437-16. Print 2017 Jul 1.

28.

High-yield production of recombinant CRM197, a non-toxic mutant of diphtheria toxin, in the periplasm of Escherichia coli.

Goffin P, Dewerchin M, De Rop P, Blais N, Dehottay P.

Biotechnol J. 2017 Jul;12(7). doi: 10.1002/biot.201700168. Epub 2017 May 15.

PMID:
28397983
29.

Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer.

Tabchi S, Blais N, Campeau MP, Tehfe M.

Cancer Chemother Pharmacol. 2017 Feb;79(2):381-387. doi: 10.1007/s00280-016-3226-0. Epub 2017 Jan 12.

PMID:
28083648
30.

Quality indicators in the management of bladder cancer: A modified Delphi study.

Khare SR, Aprikian A, Black P, Blais N, Booth C, Brimo F, Chin J, Chung P, Drachenberg D, Eapen L, Fairey A, Fleshner N, Fradet Y, Gotto G, Izawa J, Jewett M, Kulkarni G, Lacombe L, Moore R, Morash C, North S, Rendon R, Saad F, Shayegan B, Siemens R, So A, Sridhar SS, Traboulsi SL, Kassouf W.

Urol Oncol. 2017 Jun;35(6):328-334. doi: 10.1016/j.urolonc.2016.12.003. Epub 2017 Jan 3.

PMID:
28065393
31.

Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer.

Ramalingam SS, Blais N, Mazieres J, Reck M, Jones CM, Juhasz E, Urban L, Orlov S, Barlesi F, Kio E, Keiholz U, Qin Q, Qian J, Nickner C, Dziubinski J, Xiong H, Ansell P, McKee M, Giranda V, Gorbunova V.

Clin Cancer Res. 2017 Apr 15;23(8):1937-1944. doi: 10.1158/1078-0432.CCR-15-3069. Epub 2016 Oct 10.

32.

Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) - September 2015.

Albaladejo P, Bonhomme F, Blais N, Collet JP, Faraoni D, Fontana P, Godier A, Llau J, Longrois D, Marret E, Mismetti P, Rosencher N, Roullet S, Samama CM, Schved JF, Sié P, Steib A, Susen S; French Working Group on Perioperative Hemostasis (GIHP).

Anaesth Crit Care Pain Med. 2017 Feb;36(1):73-76. doi: 10.1016/j.accpm.2016.09.002. Epub 2016 Sep 20.

33.

Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab.

Tabchi S, Weng X, Blais N.

Lung Cancer. 2016 Sep;99:123-6. doi: 10.1016/j.lungcan.2016.06.026. Epub 2016 Jul 1.

PMID:
27565926
34.

Immunotherapy Comes of Age in Lung Cancer.

Khanna P, Blais N, Gaudreau PO, Corrales-Rodriguez L.

Clin Lung Cancer. 2017 Jan;18(1):13-22. doi: 10.1016/j.cllc.2016.06.006. Epub 2016 Jun 25. Review.

PMID:
27461776
35.

Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

Melosky B, Agulnik J, Albadine R, Banerji S, Bebb DG, Bethune D, Blais N, Butts C, Cheema P, Cheung P, Cohen V, Deschenes J, Ionescu DN, Juergens R, Kamel-Reid S, Laurie SA, Liu G, Morzycki W, Tsao MS, Xu Z, Hirsh V.

Curr Oncol. 2016 Jun;23(3):196-200. doi: 10.3747/co.23.3120. Epub 2016 Jun 9.

36.

Immune-mediated respiratory adverse events of checkpoint inhibitors.

Tabchi S, Messier C, Blais N.

Curr Opin Oncol. 2016 Jul;28(4):269-77. doi: 10.1097/CCO.0000000000000291. Review.

PMID:
27138570
37.

Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Kassouf W, Aprikian A, Black P, Kulkarni G, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Alam T, Brimo F, Blais N, Booth C, Chin J, Chung P, Drachenberg D, Fradet Y, Jewett M, Moore R, Morash C, Shayegan B, Gotto G, Fleshner N, Saad F, Siemens DR.

Can Urol Assoc J. 2016 Jan-Feb;10(1-2):E46-80. doi: 10.5489/cuaj.3583. Epub 2016 Feb 8. No abstract available.

38.

Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.

Zeller MP, Heddle NM, Kelton JG, Hamilton K, Wang G, Sholapur N, Carruthers J, Hsia C, Blais N, Toltl L, Hamm C, Pearson MA, Arnold DM.

Transfusion. 2016 Jan;56(1):73-9. doi: 10.1111/trf.13336. Epub 2015 Sep 24.

PMID:
26400824
39.

A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.

Ellis PM, Leighl NB, Hirsh V, Reaume MN, Blais N, Wierzbicki R, Sadrolhefazi B, Gu Y, Liu D, Pilz K, Chu Q.

Clin Lung Cancer. 2015 Nov;16(6):457-65. doi: 10.1016/j.cllc.2015.05.010. Epub 2015 Jun 2.

PMID:
26100229
40.

Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations.

Carrier M, Lazo-Langner A, Shivakumar S, Tagalakis V, Gross PL, Blais N, Butts CA, Crowther M.

Curr Oncol. 2015 Feb;22(1):49-59. doi: 10.3747/co.22.2392.

41.

Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors.

Hirsh V, Blais N, Burkes R, Verma S, Croitoru K.

Curr Oncol. 2014 Dec;21(6):329-36. doi: 10.3747/co.21.2241.

42.

A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.

Chiappori AA, Kolevska T, Spigel DR, Hager S, Rarick M, Gadgeel S, Blais N, Von Pawel J, Hart L, Reck M, Bassett E, Burington B, Schiller JH.

Ann Oncol. 2015 Feb;26(2):354-62. doi: 10.1093/annonc/mdu550. Epub 2014 Dec 2.

43.

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.

Ellis PM, Shepherd FA, Millward M, Perrone F, Seymour L, Liu G, Sun S, Cho BC, Morabito A, Leighl NB, Stockler MR, Lee CW, Wierzbicki R, Cohen V, Blais N, Sangha RS, Favaretto AG, Kang JH, Tsao MS, Wilson CF, Goldberg Z, Ding K, Goss GD, Bradbury PA; NCIC CTG; Australasian Lung Cancer Trials Group; NCI Naples Clinical Trials Unit.

Lancet Oncol. 2014 Nov;15(12):1379-88. doi: 10.1016/S1470-2045(14)70472-3. Epub 2014 Oct 15.

PMID:
25439692
44.

Maintenance therapies for non-small cell lung cancer.

Blais N, Kassouf E.

Front Oncol. 2014 Aug 19;4:213. doi: 10.3389/fonc.2014.00213. eCollection 2014. Review.

45.

Chemotherapy in Metastatic NSCLC - New Regimens (Pemetrexed, Nab-Paclitaxel).

Blais N, Hirsh V.

Front Oncol. 2014 Jul 21;4:177. doi: 10.3389/fonc.2014.00177. eCollection 2014. Review. Erratum in: Front Oncol. 2014;4:300.

46.

Managing advanced penile cancer in 2014.

Blais N, Kassouf E.

Curr Opin Support Palliat Care. 2014 Sep;8(3):241-9. doi: 10.1097/SPC.0000000000000075. Review.

PMID:
25029393
47.

Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).

Richter S, Ruether JD, Wood L, Canil C, Moretto P, Venner P, Gingerich J, Emmenegger U, Eisen A, Zalewski P, Joshua A, Mukherjee SD, Heng D, Czaykowski P, Soulieres D, Blais N, Rendon R, Fleshner N, Crook JM, Sridhar SS.

Can Urol Assoc J. 2013 Nov-Dec;7(11-12):E797-811. doi: 10.5489/cuaj.1794. No abstract available.

48.

Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.

Besse B, Leighl N, Bennouna J, Papadimitrakopoulou VA, Blais N, Traynor AM, Soria JC, Gogov S, Miller N, Jehl V, Johnson BE.

Ann Oncol. 2014 Feb;25(2):409-15. doi: 10.1093/annonc/mdt536. Epub 2013 Dec 23.

PMID:
24368400
49.

Neurologic manifestations of Henoch-Schönlein purpura.

Bérubé MD, Blais N, Lanthier S.

Handb Clin Neurol. 2014;120:1101-11. doi: 10.1016/B978-0-7020-4087-0.00074-7. Review.

PMID:
24365374
50.

Canadian guideline on genetic screening for hereditary renal cell cancers.

Reaume MN, Graham GE, Tomiak E, Kamel-Reid S, Jewett MA, Bjarnason GA, Blais N, Care M, Drachenberg D, Gedye C, Grant R, Heng DY, Kapoor A, Kollmannsberger C, Lattouf JB, Maher ER, Pause A, Ruether D, Soulieres D, Tanguay S, Turcotte S, Violette PD, Wood L, Basiuk J, Pautler SE; Kidney Cancer Research Network of Canada.

Can Urol Assoc J. 2013 Sep-Oct;7(9-10):319-23. doi: 10.5489/cuaj.1496.

Supplemental Content

Support Center